Bladder Cancer, New Therapeutic Combination Reduces Death Risk by 42%
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.7 Articles
7 Articles
Oncology Lucía de Mingo ESMO 2026 The combination of durvalumab and enfortumab vedotin has been shown to significantly improve event-free survival and overall survival in patients with muscle-invasive bladder cancer who are not candidates for cisplatin treatment or reject it. This is shown by the results of a pre-specified intermediate analysis of the phase III VOLGA trial, presented at the Congress of the European Society of Medical Oncology (E…
Patients who received durvalumab and enfortumab vedotin before surgery had better survival than the control arm in the VOLGA study. Jan Oldenburg describes the findings as an important contribution.
notizie.it
(Adnkronos) - The positive results of the phase 3 'Volga' study "have shown that perioperative treatment with durvalumab in combination with
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
